Drug intelligence / Profile preview

KVX-1005

Development stage: Preclinical
Lead developer: KeViRx
Modality: Small Molecules
Administration: Parenteral

Overview

KVX-1005 is an early-stage, investigational small molecule therapeutic candidate being developed by KeViRx. Currently in the discovery phase, the specific therapeutic target and primary indication for KVX-1005 remain undisclosed. KeViRx is a biotechnology company focused on developing novel small molecule therapeutics that target microvascular leakage and inflammation, key pathologies central to multiple diseases, including acute lung injury and cancer.

Beyond the preview

Go deeper on KVX-1005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KVX-1005.

Explore the full profile